Mark D. Tyson, II, MD, MPH, presented “Enhanced Techniques of NMIBC Detection” at the 6th International Bladder Cancer Update on November 20, 2022, in Scottsdale, Arizona.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Tyson, II, Mark D. “Enhanced Techniques of NMIBC Detection” November 2022. Accessed Dec 2022. https://grandroundsinurology.com/enhanced-techniques-of-nmibc-detection
Enhanced Techniques of NMIBC Detection
Dr. Mark D. Tyson, II, MD, MPH, moderates this session by discussing the critical need for precise detection techniques in managing NMIBC. Early and accurate diagnosis is essential for effective treatment and can significantly impact the prognosis. The panel features leading experts who present the most recent developments in diagnostic technologies and methodologies.
A key focus of the discussion is the application of enhanced imaging techniques, such as blue light cystoscopy and narrow band imaging, which provide superior visualization of bladder tumors compared to traditional white light cystoscopy. These advanced techniques allow for better detection of flat lesions and carcinoma in situ, which are often missed during standard procedures. The panelists share clinical trial data and real-world experiences, demonstrating how these technologies enhance the accuracy of NMIBC diagnosis.
The panel also delves into the role of molecular markers and genetic profiling in NMIBC detection. Dr. Tyson and the experts discuss how the identification of specific biomarkers can aid in early detection and risk stratification, enabling personalized treatment approaches. They review recent studies that validate the use of urine-based tests and other non-invasive methods for detecting molecular alterations associated with bladder cancer.
In addition to these techniques, the panel addresses the importance of integrating multiple diagnostic tools to improve overall detection rates. They emphasize the need for a multidisciplinary approach, involving urologists, pathologists, and molecular biologists, to develop comprehensive diagnostic strategies.
About the 6th International Bladder Cancer Update:
The International Bladder Cancer Update (IBCU) is a CME conference focused on the diagnosis and treatment of bladder cancer. The conference offers medical professionals an opportunity to listen to updates from, and interact with, expert international faculty to improve knowledge and determine best treatment practices to improve patient outcomes. IBCU encompasses expert lectures, interactive discussions, a panel roundtable, debates, and case presentations. It is physician-led, multi-supported, and designed for urologists, urologic oncologists, and other healthcare professionals involved in the treatment of bladder cancer.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Mark D. Tyson II, MD, MPH, is a urologic oncologist and Associate Professor of Urology with the Mayo Clinic Alix School of Medicine in Scottsdale, Arizona. Dr. Tyson completed his medical education at Dartmouth Medical School and holds a Masters in Public Health, with an emphasis in Epidemiology and Biostatistics, from the Harvard T. H. Chan School of Public Health. He completed a urology and surgical residency at the Mayo School of Graduate Medical Education at the Mayo Clinic College of Medicine, going on to complete a fellowship in urologic oncology from the Vanderbilt University School of Medicine. His clinical focus includes treatments for bladder cancer, including single port radical cystectomy with urinary diversion.Dr. Tyson is active in research and education, providing mentorship to trainees. He authors expert content and publishes regularly in scientific journals.
